March 1, 2018 (Vol. 38, No. 5)
The Edit-R CRISPRa platform provides researchers interested in gain-of-function studies with a powerful and easy-to-use two-component system for drug discovery, disease modeling, or pathway analysis. The system is available in lentiviral and synthetic formats and is well-suited for robust overexpression in virtually any cell system. This format is also highly amenable to arrayed studies for high-throughput, complex phenotypic analysis. The Edit-R CRISPRa portfolio includes genome-wide, predesigned guide RNAs for human and mouse, as either a lentiviral expression plasmid, lentiviral particles, or a two-part synthetic guide RNA. The system further utilizes nuclease-deactivated Cas9 fused to three activation domains provided as lentiviral particles or purified plasmids.